Brief: REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Regenxbio

14/01/2025 12:52

Jan 14 (Reuters) - Regenxbio Inc  RGNX.O :
    * REGENXBIO AND NIPPON SHINYAKU ANNOUNCE EXCLUSIVE
PARTNERSHIP TO
DEVELOP AND COMMERCIALIZE RGX-121 AND RGX-111 FOR MPS DISEASES
    * REGENXBIO INC - TO RECEIVE $110 MILLION UPFRONT, UP TO
$700
MILLION IN MILESTONES
    * REGENXBIO INC - RETAINS RIGHTS TO RGX-121 PRIORITY REVIEW
VOUCHER

Source text:  ID:nPn5BHy6Wa 
Further company coverage:  RGNX.O 

 ((Reuters.Briefs@thomsonreuters.com;))